Soluble Expression of a Neo2/15-Conjugated Single Chain Fv against PD-L1 in Escherichia coli
- Authors
- Kim, S.-H.; Jeong, H.-J.
- Issue Date
- 1-Jan-2022
- Publisher
- MDPI
- Keywords
- Immunocytokine; Neo2/15; Programmed death-ligand 1; Recombinant fusion protein; Single chain Fv
- Citation
- Current Issues in Molecular Biology, v.44, no.1, pp.301 - 308
- Journal Title
- Current Issues in Molecular Biology
- Volume
- 44
- Number
- 1
- Start Page
- 301
- End Page
- 308
- URI
- https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/25294
- DOI
- 10.3390/cimb44010022
- ISSN
- 1467-3037
- Abstract
- Immunocytokines, antibody-cytokine fusion proteins, have the potential to improve the therapeutic index of cytokines by delivering the cytokine to the site of localized tumor cells using antibodies. In this study, we produced a recombinant anti-programmed death-ligand 1 (PD-L1) scFv, an antibody fragment against PD-L1 combined with a Neo2/15, which is an engineered interleukin with superior function using an E. coli expression system. We expressed the fusion protein in a soluble form and purified it, resulting in high yield and purity. The high PD-L1-binding efficiency of the fusion protein was confirmed via enzyme-linked immunosorbent assay, suggesting the application of this immunocytokine as a cancer-related therapeutic agent. : © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Science and Technology > Department of Biological and Chemical Engineering > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/25294)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.